Abstract-It is largely unknown to what extent genetic abnormalities contribute to the development of atherosclerotic renal artery disease. Among the potential candidate genes, those of the renin-angiotensin system and the endothelial nitric oxide synthase (eNOS) rank high because of their importance in the atherosclerotic process. We investigated the association of polymorphisms in these genes (the angiotensinogen Met235Thr, the angiotensin-converting enzyme insertion/deletion, the angiotensin II type-1 receptor A1166C, and the eNOS Glu298Asp) with the presence or absence of atherosclerotic renovascular disease in 456 consecutive hypertensive patients referred for renal angiography on the suspicion of renovascular hypertension. Nondiseased normotensive (nϭ200) and hypertensive (nϭ154) patients from a family practice served as external controls. Renal artery disease was present in 30% of our angiography group. The Asp allele of the eNOS Glu298Asp polymorphism was associated with atherosclerotic renal artery stenosis with an odds ratio of 1.44 (95% confidence interval 1.00 to 2.09) versus hypertensives with angiographically proven patent arteries, of 1.89 (1.24 to 2.87) versus hypertensive family practice controls, and of 2.09 (1.29 to 3.38) versus normotensive family practice controls. However, this allele also differed significantly between patients with patent renal arteries and normotensive and hypertensive controls. No differences were found with respect to the other genetic polymorphisms. We hypothesize that the Asp allele of the Glu298Asp polymorphism may predispose to the development of atherosclerotic lesions but that renal artery involvement depends on other factors, also. 
A therosclerotic renal artery stenosis (ARAS) is a relatively common cause of secondary hypertension. 1 Today, most investigators consider this abnormality to be part of a generalized atherosclerotic complex with an etiological background similar to extrarenal atherosclerosis.
Although it is still largely unknown if and to what extent genetic abnormalities contribute to the development of this disease, polymorphisms in genes of the renin-angiotensin system rank high among the potential candidates. For instance, the D allele of the insertion/deletion variant of the angiotensin-converting enzyme (ACE) gene has been associated with atherosclerotic disease, 2, 3 and it is conceivable that this is true also for ARAS. Another genetic variant that could have a bearing on the renal vasculature is the angiotensin II type 1 receptor A1166C (AT 1 R A 1166 C) polymorphism. Patients homozygous for the C allele of this polymorphism have increased sensitivity to angiotensin II 4 and may, in combination with the DD genotype of the ACE gene, have an increased risk of cardiovascular complications. 5 Finally, the angiotensinogen Met235Thr (AGT Met235Thr) polymorphism is of interest because the Thr allele of this polymorphism is associated with high plasma levels of AGT and increased responsiveness to angiotensin II. 6 In addition to studies of angiotensin II and its precursors, many studies have highlighted the importance of endothelium-derived nitric oxide (NO) in inhibiting atherosclerotic disease and the possibility that impairment of endothelial NO production promotes atherosclerosis. NO is produced by endothelial nitric oxide synthase (eNOS). The gene encoding eNOS has a G-to-T polymorphism at position 894 leading to substitution of Glu by Asp at codon 298 of the eNOS protein.
The mutant allele is associated with a reduced response to the eNOS inhibitor L-NMMA in healthy volunteers 7 and may be related to the occurrence of atherosclerotic complications.
Although a few earlier studies have addressed the possible role of candidate genes such as the ones described in renovascular disease, 8 -11 none of these has been performed in patient populations that were primarily selected for their risk for ARAS. This is important because of the complex yet unresolved relation between anatomical abnormalities and clinical symptoms of renovascular disease. 12 In the present study, therefore, we have examined the distribution of the alleles of the aforementioned 4 candidate genes in a group of patients in whom renovascular hypertension was clinically suspected and who all underwent renal angiography for this reason.
Methods

Patients
Between January 1995 and December 2002, 456 patients referred to our outpatient clinic for evaluation of their hypertension underwent renal angiography. Hypertension was defined as systolic blood pressure Ͼ140 mm Hg or diastolic blood pressure Ͼ90 mm Hg on at least 3 occasions. All patients fulfilled 1 or more of the following criteria: persistent elevation of blood pressure despite the use of 2 or more antihypertensive drugs, accelerated hypertension, documented atherosclerotic vascular disease in 2 or more vascular beds, the presence of an abdominal bruit, or unexplained impairment of renal function in response to antihypertensive treatment.
Since mid 1996, we ask for written permission from all newly referred patients to draw a 3-mL blood sample for genetic analysis, as approved by the local Medical Ethics Committee. Patients who had undergone angiography between January 1995 and June 1996 were sent a letter with the request to visit our laboratory to donate a blood sample. Medical history and risk factor profiles were derived from the clinical files.
Two experienced readers evaluated all angiographic films and reported on the site and nature of the aberration and the (maximum) percent stenosis via standardized forms. If the 2 estimates of the degree of stenosis differed by Ͼ10%, then a third opinion was decisive. Because there is no consensus on what degree of renal artery narrowing is hemodynamically significant and because atheromatous renal artery abnormalities are likely to progress in time, 13 we divided our study participants into 2 groups: (1) patent renal arteries and (2) (any grade of) atheromatous renal artery disease. Patients with nonatheromateous renal artery disease (mainly fibromuscular dysplasia) were excluded from analysis.
Control Populations
Hypertensive (nϭ154) and normotensive (nϭ200) subjects from the HIPPOCRATES study, which is an ongoing study on cardiovascular risk and genetics in a general practice in Kerkrade, the Netherlands, served as control groups for the ACE insertion/deletion, the angiotensin II type-1 receptor A1166C, and the eNOS Glu298Asp genotype distributions. The details of the enrollment of the study participants have been published previously. 14 
Genetic Analysis
Genetic analysis was performed as previously described 14 (the primers used for detection of the angiotensinogen Met235Thr, the ACE insertion/deletion, the angiotensin II type 1 receptor A1166C, and the eNOS Glu298Asp polymorphisms can be found in an online supplement available at http://www.hypertensionaha.org.).
Statistical Analysis
Statistical significance for differences in quantitative variables was tested by unpaired t tests or Mann-Whitney tests when appropriate. Allele and genotype frequencies and other qualitative data were analyzed using 2 tests. Hardy-Weinberg equilibrium was tested using standard methods. 15 Genetic models were further evaluated by logistic regression analysis to "correct" for those variables (confounders), which would alter the interpretation of the relationship between genotype and presence of renal artery abnormalities when not included in the model. 16 We regarded age, sex, body mass index, pulse pressure, and renal function as potential confounders. We choose to regard only pulse pressure of the blood pressure parameters in our analysis because imputing systolic blood pressure (SBP) and diastolic blood pressure (DBP) as well would inevitably lead to collinearity (Pearson correlation coefficients were 0.83 for pulse pressure versus SBP, 0.28 for pulse pressure versus DBP, and 0.76 for SBP versus DBP; PϽ0.0001 for all). We introduced the potential confounders independently into a model that contained genotype and assessed the change of the regression coefficient of the central determinant (genotype). The variable that led to the greatest change was retained in the model, provided that this change was at least 10%. The remaining potential confounders were then introduced again into the new model (containing genotype and the confounder). This was repeated until no more variables had to be retained.
Interactions between 2 polymorphisms were tested in models that included the alleles (risk allele present or not present), the interaction between the 2, and confounders when applicable. We assumed that both groups from the family practice contained no subjects with renal artery stenosis. However, previous studies suggest that secondary hypertension is present in Ϸ5% of hypertensive patients and renovascular hypertension in Ϸ1%. [17] [18] [19] [20] To the best of our knowledge, no such data are available on the presence of incidental renal artery stenosis in subjects without hypertension, but conceivably this value is much lower. We tested the robustness of statistically significant results in the hypertensive group by a sensitivity analysis 21 by modeling odds ratios after deleting 5% of the subjects in this group with all possible alleles. Data are expressed as meanϮSD or median (interquartile range) or odds ratio (95% confidence interval) unless indicated otherwise. A 2-sided PϽ0.05 was considered statistically significant. Statistical analyses were performed with SPSS 10.0 for Windows (SPSS Inc).
Results
Patient Characteristics
Of the 456 patients who underwent angiography, genotyping was available in 401 (88%). The remainder did not differ from the genotyped patients regarding demographics or important potential confounders. Thirty-three of the 401 patients had fibromuscular dysplasia diagnosed and, therefore, were excluded from analysis. Thus, the present report is based on the remaining 368 subjects. In 109 (30%) of these, atherosclerotic renal artery abnormalities were present, among which there were 70 (19%) with a renal arterial lumen reduction of Ͼ50%.
General characteristics of the 4 study groups are presented in Table 1 . As expected, normotensive and hypertensive controls from the general practice had lower SBP, DBP, and pulse pressures in comparison to the subjects with renal artery stenosis. In addition, they were more often female and had higher body mass index (although not statistically significant in the normotensive group). Normotensive controls were slightly older than the angiography group, whereas the hypertensive controls were a bit younger. In the angiography group, patients with renal artery stenosis (ARASϩ) presented with a worse cardiovascular risk profile than individuals with nondiseased renal arteries (ARASϪ). They were older, more often male, and had a longer history of hypertension (6 [ 
Genetic Analyses
The distribution of the polymorphisms in the control populations was compatible with the Hardy-Weinberg equilibrium, whereas this was not the case in the angiography group with respect to the eNOS Glu298Asp (only ARASϪ) and the AGT Met235Thr polymorphisms. (Table 2 ). No differences in either genotype or allele frequencies were found between the normotensive and the hypertensive control group.
Normotensive Controls Versus Patients With ARAS؉
The distribution of the eNOS Glu298Asp polymorphism was different between normotensive controls and subjects with renal artery disease ( 2 ϭ17.6; PϽ0.0001). When the presence of renal artery disease was taken as a dependent variable in logistic regression and the Glu/Glu as reference category, the odds ratios of the Glu/Asp and Asp/Asp genotypes were 1.33 (0.79 to 2.26) and 4.45 (2.13 to 9.30), respectively. After correction for pulse pressure, sex, and age, the odds ratios The AGT Met235Thr polymorphism was not investigated in the HIPPOCRATES study, and this information is therefore lacking in these subjects. Bold indicates genotype distributions that are not in Hardy-Weinberg equilibrium.
ARAS indicates atherosclerotic renal artery stenosis. *n indicates the number of alleles. To allow comparison with data from the angiography group, we also performed analysis of allele frequencies, which yielded comparable results ( Table 3 ). The frequency of the ACE insertion/deletion and the ATR1 A1166C polymorphisms did not differ between controls and patients with renal artery stenosis. There were no interactions between the polymorphisms.
Hypertensive Controls Versus Patients With ARAS؉
Genotype frequencies of the eNOS Glu298Asp polymorphism were different between hypertensive controls and subjects with renal artery disease ( 2 ϭ10.2, Pϭ0.006). When the presence of renal artery disease was taken as a dependent variable in logistic regression and the Glu/Glu as reference category, the odds ratios of the Glu/Asp and Asp/Asp genotypes were 1.22 (0.69 to 2.18) and 2.88 (1.33 to 6.23), respectively. After correction for pulse pressure and sex, the odds ratios were 1.29 (0.66 to 2.53) and 4.17 (1.73 to 10.05), respectively. Analysis of allele frequencies yielded comparable results (Table 3 ). This association remained even when one would assume that 5% of the hypertensive controls had incidental renal artery stenosis (and therefore would have had to be excluded from analyses). For details, please see the online supplement. The frequencies of the ACE insertion/ deletion and the ATR1 A1166C polymorphisms did not differ between controls and patients with renal artery stenosis. There were no interactions between the polymorphisms.
Angiography Group: ARAS؊ Versus ARAS؉
The genotype frequency distribution was not different with regard to the polymorphisms undergoing study. Because there was no Hardy-Weinberg equilibrium with respect to the eNOS Glu298Asp and the AGT Met 235 Thr polymorphisms, we also tested differences in allele frequency. Again, this did not yield significant results. However, logistic regression analysis showed that the Asp allele had an odds ratio of 1.44 in comparison to the Glu allele on ARAS, conditionally on estimated creatinine clearance (Table 3 ). There were no interactions between the polymorphisms.
ARAS Versus Controls
When the ARASϪ group was contrasted with the 2 general care control groups, the Asp allele appeared to be significantly more frequent in ARASϪ than in both control groups. For details, see the online supplement.
Discussion
The objective of our study was to investigate the association of several candidate genes with ARAS in a population of patients with hypertension and clinical clues suggesting the presence of renal artery stenosis. All patients were subjected to angiography and the prevalence of renal artery abnormalities in this group was 30%. We found that patients with ARAS (ARASϩ) were more often carriers of the Asp allele with regard to the eNOS Glu298Asp polymorphism. Because this association only just reached statistical significance, we sought for additional evidence that the association was a genuine one. Therefore, we compared ARASϩ to 2 sets of nondiseased controls: 1 of hypertensive and 1 of normotensive subjects, who were drawn from a family practice. Again, the Asp allele had a significantly higher prevalence in patients with renovascular disease. Nevertheless, even the use of these control groups is not free of assumptions. The prevalence of renal artery stenosis among hypertensive patients in population samples is, reported to be low, Ϸ1%. [17] [18] [19] [20] Still, we remain uncertain about the true prevalence of ARAS in controls. However, model analysis showed that our results are robust to a low prevalence of this condition in the control group. Furthermore, the Maastricht hospital is the nearest academic center, but it is not the closest hospital. This implies that patients from Kerkrade with a moderate severe clinical picture have a lower probability of undergoing renal angiography in Maastricht than patients with similar symptoms from the Maastricht region and will therefore be underrepresented in this study. Yet, we have no clues indicating that our current controls from a general care practice are any different from a random selection of subjects from a general practice in Maastricht.
Positive findings in an association study can be attributed to 3 situations. First, the allele itself directly affects the expression of the phenotype. Second, the allele is in linkage disequilibrium with another allele that is responsible for the effect. Third, the association is brought about by confounding or selection bias. 22 Whereas the first 2 situations do not hamper the use of a polymorphism for predicting the presence of a condition, the third obviously does. One of the major concerns in this respect is the presence of selection bias. The routine use of the Hardy-Weinberg equilibrium test has been advocated to reduce false-positive findings. 23 Hardy-Weinberg equilibrium was absent in ARASϪ. We can only speculate about the explanation for this phenomenon, but it is very likely to be related to the fact that these patients are not truly healthy controls. The under-representation of heterozygotes in ARASϪ especially suggests that the presence or absence of the Asp allele itself may have influenced the van Onna et al Candidate Genes in Renal Artery Diseasechance for an individual being selected for angiography according to our criteria. Our finding of an association between the presence of renal artery stenosis and the eNOS Glu298Asp polymorphism should be interpreted cautiously because the prevalence of Asp carriers was also higher in the ARASϪ group than in the control groups. This implies that the ARASϪ group differed from controls by a (unmeasured) variable (or possibly variables) that coincides with the differences in genotype distribution of the eNOS Glu298Asp polymorphism. Although we cannot rule out that the mutant gene polymorphism is associated with more severe hypertension, because both ARASϪ and ARASϩ patients had substantially higher blood pressure than controls, this option does not fully explain the data either, because we accounted for blood pressure differences by logistic regression analysis. Although the introduction of pulse pressure in the logistic regression analysis may seem debatable because we cannot rule out causality (via the possible scenario that the Asp allele leads to a high pulse pressure, which subsequently causes angiographically detectable ARAS), we found that the odds ratio on renal artery stenosis increased when pulse pressure was accounted for. In case of causality, we would have expected a decrease of the odds ratio in the adjusted model. Moreover, all reports regarding blood pressure or presence of hypertension and the eNOS Glu298Asp polymorphism in whites are negative. 24 -28 Alternatively, (differences in) the total burden of atherosclerosis may account for our findings. Other investigators previously found the eNOS Glu298Asp polymorphism to be related to the presence of atherosclerotic manifestations such as coronary artery disease 29 -31 and carotid atherosclerotic plaques, 32 although negative reports have also been published. 28 Because atherosclerotic renovascular disease is generally viewed as a local manifestation of systemic atherosclerotic disease, at least our data in ARASϩ are in line with these earlier observations. Even the results in ARASϪ patients may be compatible with more severe atherosclerosis in these individuals. The absence of atherosclerotic lesions in renal arteries does not at all exclude the presence of atherosclerosis elsewhere in the vascular system, and 22% of the ARASϪ patients had experienced signs of extrarenal atherosclerosis. Moreover, it is likely that normotensive and hypertensive patients with relatively mild forms of hypertension in a general care practice have lower amounts of (extrarenal) atherosclerosis than patients in an outpatient clinic of a tertiary referral hospital who are suspected of having renal artery stenosis. In this respect, the difference between ARASϪ and ARASϩ, namely proven renal artery atherosclerosis, may just be a marker of more widespread atherosclerosis. Indirectly, this hypothesis is supported by the differences between the groups regarding pulse pressure, which is commonly associated with the severity of atherosclerosis, although it cannot be ignored that ARASϩ had a far worse risk profile. Yet, because the extent of extrarenal atherosclerosis was not investigated in our study, we cannot exclude other explanations. 22, 23, 33 The most obvious candidate genes to look at when renal artery disease is the object of study, the ones of the renin-angiotensin system, were evenly distributed among all groups, at least with respect to the polymorphisms in the genes that we studied. Only a few studies have focused on the association between ARAS and genetic polymorphisms, and all have addressed the ACE insertion/deletion polymorphism. 8 -11 Two groups compared the distribution of the ACE insertion/ deletion genotypes between ARAS and normotensive groups and found the D allele to be more prevalent in ARAS. 9, 11 The AGT Met 235T and the ATR1 A1166C polymorphisms were not found to be associated with ARAS. 11 When, however, patients with ARAS were compared with patients with diffuse atherosclerotic disease who underwent angiography on the suspicion of aortic aneurysm, no association was found with the ACE genotype. 8 The only study that compared hypertensive patients with renal artery stenosis to hypertensive patients without renal artery stenosis found an overrepresentation of DD homozygotes in the renal artery stenosis group, 10 but it must be emphasized that in only 38% of the patients angiography of the renal arteries was performed on the suspicion of renovascular hypertension. Our study is the first to our knowledge to examine 3 different polymorphisms of the renin-angiotensin system in hypertensive patients who were all selected according to the same criteria for angiography. With our standardized approach, we did not find an association between these genotypes and ARAS.
Perspectives
Taking all data together, we hypothesize that the Asp allelle of the eNOS Glu298Asp polymorphism predisposes to (systemic) atherosclerosis but that the extent of the lesions, among which are those in the renal arteries, depends also on additional risk factors. Considering the importance of endothelium-derived nitric oxide in atherosclerosis, our findings fit very well in the theoretical framework of atherosclerotic disease and merit further research into the mechanisms whereby altered nitric oxide production in conjunction with other cardiovascular risk factors may cause systemic and/or renal atherosclerosis.
